- Applied DNA Sciences Inc (NASDAQ: APDN) has initiated analytical validation of a company-developed, PCR-based monkeypox virus test specific to the genetic signature of the monkeypox virus.
- The test has been developed as an NYSDOH Laboratory Developed Test (LDT) type.
- If Applied DNA validates the test, a validation package will be submitted to the New York State Department of Health (NYSDOH) for approval.
- If approved, the test will be used to power ADCL's monkeypox testing services.
- Applied DNA's monkeypox test utilizes an A17L gene-target specific to monkeypox that enables the qualitative detection and differentiation of the monkeypox virus from other non-variola orthopoxviruses using real-time PCR.
- California Governor Gavin Newsom declared a state of emergency over the monkeypox.
- California confirmed 827 monkeypox cases, the second-largest state tally after the 1,390 infections documented in New York, according to the U.S. Centers for Disease Control and Prevention.
- Price Action: APDN shares are up 236.3% at $2.29 during the market session on the last check Tuesday.
Read at Benzinga